Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Gensaic","sponsor":"CF Foundation","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Gensaic Receives Funding From the CF Foundation to Develop a Gene Therapy for People With Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Gensaic

    Menu

    Gensaic

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Gensaic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Gensaic Receives Funding From the CF Foundation to Develop a Gene Therapy for People With Cystic Fibrosis

              Details:

              Gensaic will use the net proceeds to develop full CFTR gene delivery to lung tissue using its proprietary phage-derived particle (PDP) platform in CFTR-based gene Therapy.

              Lead Product(s): CFTR-based Gene Therapy

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: CF Foundation

              Deal Size: $3.5 million Upfront Cash: Undisclosed

              Deal Type: Funding January 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY